GRIS-PEG
LOE ApproachingNDAORALTABLET
Approved
Apr 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
GRIS-PEG by Bausch + Lomb. Approved for the following ringworm infections. First approved in 1975.
Drug data last refreshed 11m ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GRIS-PEG is an oral tablet formulation of griseofulvin, a fungistatic antifungal agent approved in 1975 for treating ringworm infections caused by Microsporum, Epidermophyton, and Trichophyton species. The drug deposits in keratin precursor cells and binds tightly to new keratin, rendering it resistant to fungal invasion. GRIS-PEG represents a microcrystalline formulation designed for systemic oral antifungal therapy.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling downsizing commercial teams and transition focus to generic defense or pipeline support roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
GRIS-PEG offers limited career advancement potential due to its legacy status, approaching LOE, and zero linked job openings. Roles in this space are defensive and decline-focused, suitable only for professionals managing portfolio wind-down or seeking stability in non-growth therapeutic areas.
Brand Manager
Worked on GRIS-PEG at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.